# Phase I Study of XZ120 in Malignant Tumors

> **NCT06206915** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 123 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** XZ120 injection

## Key facts

- **NCT ID:** NCT06206915
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2025-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 123 (ESTIMATED)
- **Last updated:** 2024-01-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06206915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06206915, "Phase I Study of XZ120 in Malignant Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06206915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*